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Background: It is becoming a standard practice worldwide for cancer patients to be discussed by a
multidisciplinary team (MDT or ‘tumour board’) in order to formulate an expert-derived management
plan. Evidence suggests that MDTs do not always work optimally in making clinical decisions and that
not all MDT decisions get implemented into care. We investigated factors inﬂuencing decision-making
and decision implementation in cancer MDTs.
Methods: Semi-structured interviews were carried out with expert MDT members of Urological and
Gastro-Intestinal tumours of 3 London (UK) hospitals. The standardised interview protocol assessed MDT
experts’ views on decision-making, barriers to reaching a decision and implementing it into care, and
interventions to improve this process. All interviews were audio-taped, transcribed verbatim and ana-
lysed using a standardised approach. Emergent themes were identiﬁed by 2 clinical coders and tabulated.
Results: Twenty-two participants participated in the study and data collection achieved ‘saturation’ (i.e.,
similar themes raised by different participants). Barriers to clinical decision-making included: inade-
quate clinical information; lack of investigation results; non-attendance of key members; teleconfer-
encing failures. Barriers to implementation of MDT recommendations included: non-consideration of
patients’ choices or co-morbidities; disease progression at the time of implementation. Proposed in-
terventions included improving the information available for the discussion through a standardised
proforma; improving video-conferencing; reducing the MDT caseload (e.g., via selective MDT review of
certain patients); and including patients more in the decision process.
Conclusions: There is an increasing drive to improve the clinical role of the MDT within cancer care. This
study demonstrates the main barriers that MDTs face in deciding on and, importantly, implementing a
management plan. Further research should prospectively evaluate interventions to enhance translation
of MDT decision-making into cancer care and thus to expedite and improve care.
Crown Copyright  2013 Published by Elsevier Ltd on behalf of Surgical Associates Ltd. All rights
reserved.1. Introduction
Increasing complexity of cancer treatment led to the introduc-
tion of multidisciplinary teams (MDTs e termed ‘tumour boards’ in
the USA) for diagnosing and treating cancer diseases in many
countries. In the UK, this multidisciplinary approach has been
deﬁned at cancer care policy level and acknowledged by thend Cancer, Imperial College
ospital, London W2 1PG, UK.
013 Published by Elsevier Ltd on bNational Comprehensive Cancer Network, which has described the
core members that constitute an MDT.1 MDTs consist of medical
and surgical personnel (surgeons, oncologists, histopathologists,
and radiologists), nurses (clinical nurse specialists, research nurses
for clinical trial recruitment) and allied health professionals (di-
eticians, scientists, and others). The MDT serves as a mean to
improve communication and decision-making between many
healthcare professionals involved in delivering cancer care and the
patients.2 MDTs thus aim to bring together the requisite expertise
to deliver high-quality cancer care and, ultimately, they are inten-
ded to improve survival.3
Since inception of MDTs almost 20 years ago4 and their imple-
mentation in the UK5 and other parts of the world,6e10 there hasehalf of Surgical Associates Ltd. All rights reserved.
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meetings.8 Some attempts have been made to link MDT-delivered
care with survival rates3,11e16 e however, the evidence of this link
to date is rather patchy and future research is hampered by the fact
that MDTs in countries where they are widely used like the UK are
now the standard of care and hence randomised trials of their
effectiveness cannot take place. Looking back at the purpose of
establishing MDTs, which was to streamline and improve the de-
livery of cancer services, the MDT’s chosen treatment and its
implementation can be used as potential measures of performance
e beyond survival (which, in addition, can be affected by many
factors and hence it is very difﬁcult to attribute potential
improvement to the MDT part of the care pathway). Along such
lines, the appropriateness of a team’s decision-making and the
success in reaching a treatment planwhen ﬁrst reviewing a patient
have recently been proposed in the surgical literature to be po-
tential markers of the quality of the MDT meeting.17e19
Some research to date has assessed the performance of the MDT
by whether the recommendations made by the team get imple-
mented subsequent to the meeting.20e23 These studies, carried out
via comparing what the MDT decided or recommended and what
treatment the patient actually received through examining patient
records, show that 4e15% of MDT recommendations do not get
carried out. Key reasons for such discordance between the MDT
recommendations and the ﬁnal administered treatment are
patient-related factors of co-morbidities and patient preferences.
Real-time observational assessments of MDTs complement these
ﬁndings by showing that patient factors are often not considered by
the MDT members at the time of decision-making.18,24,25
In this study, we investigate the views of expert urology and
gastro-intestinal cancer service providers in relation to the effec-
tiveness of their MDTs in reaching a recommendation for each
presented patient and subsequently implementing this recom-
mendation into patient care.We speciﬁcally investigate the barriers
in implementing MDT decisions into patient care and how these
can be overcome to streamline cancer care.
2. Methods
2.1. Design
A qualitative, semi-structured interview-based approach was employed to
investigate key issues surrounding MDT decision-making and decision imple-
mentation in urological and gastro-intestinal (GI) tumours. Qualitative techniques
based on expert contributions are appropriatewhen complex clinical issues are to be
investigated and experts’ views are sought regarding care processes.26,27 The out-
puts of such studies are subsequently used as a basis for large scale surveys, expert
consensus development, or the development of interventions. Within our research
group, we have used semi-structured interviewswith surgeons in studies of surgical
decision-making,27 surgical performance,28,29 and recently urology MDT decision-
making.18
2.2. Participants and procedure
Semi-structured face-to-face interviews with a purposive sample of MDT
members across urology and GI Surgery were carried out by a surgeon researcher
trained in qualitative methods (RJ). Participants included Urologists, GI surgeons,
Oncologists, Cancer nurses, Radiologists and Histopathologists. In qualitative studies
such as this one, the key issue in participant selection is that the participants can
provide information on the topic of the interview in some depth. Participant
numbers, as such, are of lesser importance, provided the themes that emerge from
the interviews are recurring (‘thematic saturation’ criterion30; this was achieved in
the present study). A purposive sample of representative members of both GI and
urology teams across 3 hospitals in London, UK, was interviewed to reﬂect views
from a range of perspectives. The study hospitals were chosen based on convenience
(to ensure we had access to participants) and they were representative of a range of
hospitals providing cancer care services to GI and Urology cancer patients e
including inner city and community institutions. Participation was voluntary,
informed consent was obtained, and anonymity was ensured throughout the study.
An interview protocol was developed (the protocol is supplied in the Appendix),
focusing on MDT members’ views on: decision-making and barriers to reaching adecision at the MDT meeting; implementation of MDT decisions and factors inﬂu-
encing implementation; strategies to improve MDT decision-making and decision
implementation. Participants were also asked questions related to the venue and
teleconferencing facilities of their MDTs, and demographic information. To ensure
face and content validity, the protocol was based on some recent ﬁndings of our
review of the literature regarding effectiveness of MDTs and the process they use to
review patients and make care recommendations17,31 and also of recent qualitative
ﬁndings on the same topic.18,32 Each interview lasted 15e25 min and was audio-
taped and transcribed verbatim.
2.3. Data analysis
To ensure accuracy in representing the participants’ views and minimisation of
researcher bias, a standardised approach to interview analysis was taken. After a
joint analysis of two interviews, a coding framework of emerged common themes
was developed by two trained clinical researchers (RJ: surgeon; MA: physician
trained in qualitative methods) to analyse all the interviews independently in order
to identify emergent themes as per standard qualitative research practice.30 Dis-
agreements were resolved through discussion. The analysis was reviewed by a
psychologist with extensive experience in patient safety and qualitative research
(NS) and emergent themes tabulated alongside verbatim quotes for illustration.3. Results
3.1. Participants
Twenty-twoMDTmembers (Surgeons/Physicians of Consultant/
Attending level, experienced nurses) participated in the study
(Urologists ¼ 5, Uro-oncologists ¼ 3, Urology Nurses ¼ 3,
Histopathologists¼ 1, Radiologists¼ 1, GI surgeons¼ 4, GI Nurses¼
3 and GI Oncologists ¼ 2) across 3 different hospitals in the wider
London (UK) region.
The themes that emerged from the interviews and illustrative
verbatim quotations are summarised below.3.2. Venue and facilities of the MDT
Mostparticipants (Surgeons¼7,Oncologists¼5,Nurses¼2) said
that their MDT meeting is held in a dedicated room equipped with
video-conferencing facilities. Althoughuseful for teamscalling into a
cancer centre, video-conferencing can interfere with the meeting
and impede teamwork and team decision-making (Table 1).3.3. Decision-making at the MDT meeting
Participants reported that in the majority of patients a man-
agement plan was decided at the MDT meeting (median response
to the question “how often are you able to reach a management plan
after case discussion”: 92% range 80e99%). Factors affecting nega-
tively the team’s decision-making are summarized in Table 2 and
discussed in detail below.
3.3.1. Inadequate information
Participants reported that lack of necessary information ob-
structs decision-making: “... Well, some relevant crucial bit of history
which no one is able to give us and not been stated in the letter and we
feel we can’t make a decision without that information” (Surgeon 8).
Themajority of participants (n¼ 16) reported that unavailability
of investigation results hampered decision-making: “... you may be
awaiting a scan or pathology results, which you don’t have ...” (Sur-
geon 4).
The patient’s co-morbid state was reported as an elemental part
of the information required for the MDT to make a decision: “... Just
to give a quick example, if a patient has a treatable prostate cancer and
he has no mobility? There is no way they can commute to the radio-
therapy section ﬁve days a week for seven and a half weeks to have
radiotherapy to their pelvis ...” (Surgeon 2).
Table 1
Disadvantages of video-conferencing at a cancer multidisciplinary team meeting.
Problems associated with video-conferencing Representative quotes
On-going technological problems with
the equipment
“It cuts out every hour, so the units have to be reconnected after an hour. So you get a 2 min break there,
and a lot of the time, especially at the X site, it breaks down, so you can’t see any radiological images” (Surgeon 1).
Poor communication within the team “There’s a lot of mumbling going on, there’s a lot of static, sometimes it cuts out” (Surgeon 1).
“It’s less personal; and it’s also difﬁcult especially when more than one person wants to speak at the same time
and there’s a little bit of a lag. So that’s obviously not the same as face-to-face when you can take turns in
speaking” (Surgeon 5).
Direct negative impact on clinical
decision-making
“If you can’t get links then it may only be one urologist making the decision, it could delay treatment if it’s
more complex” (Nurse 2).
Cause of conﬂict and frictions within
the team
“Communication in video-conferencing is not ideal because it tends to cause divisions between the two
groups on the different sides when there’s a change in treatment decision. So video-conferencing may lead to
tribalism, and what tends to happen is humans who are in the same room as each other tend to stick together,
and therefore it creates tension between the two groups” (Oncologist 3).
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the actual status of the patient also impact on decision-making “... I
saw aman, he came tome as a second opinion a fewweeks ago, and he
ran up all the stairs here... He’d got a letter from the ﬁrst oncologist
saying, ‘I amvery sorry, youare 76,wedonot treat anyone over 75... You
can’t have radiotherapy.’ ...And he went sailing every weekend, he went
rock climbing e he was the ﬁttest 76 year old ever...” (Oncologist 2).
Concernwas expressed as towhether theMDTcould ever evolve
to consider patient management to wholly take account of patients’
wishes: “... It’s key that the patient’s wishes, their performance status,
their abilities and their social status is taken into account when
making decisions. And you can’t do that with a MDT, it’s not a simple
issue...” (Surgeon 3).
3.3.2. Non-attendance of key team-members
Treatment decisions are formulated by a team thus the presence
of the core team-members is necessary. A ﬁrst consequence of a
core member’s absence is that the decision may be delayed to the
detriment of the patient: “Sometimes the consultant who’s in charge
of that patient hasn’t attended the meeting and therefore they need to
wait until the next meeting and he’s there to allow a decent discussion”
(Surgeon 5).
Furthermore, making a decision when a key team-member is
absent may lead to an inappropriate treatment plan: “I was away at
an MDT meeting a few weeks ago. The MDT recommended not to treat
a person with salvage therapy for recurrent prostate cancer. They
hadn’t seen the patient. The patient was 81 but he was a very ﬁt guy, he
was insistent he wanted treatment and that didn’t come up at the
MDT, so again, that patient opinion was missing and the co-morbidity
was missing at the MDT and I actually overruled it...” (Surgeon 1).Table 2
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Inadequate information
History 8 4 3
Co-morbidities 5 2 3
Psychosocial factors 2 3 3
Investigation results 8 4 5










2 1 43.3.3. Time pressure
Respondents reported that they spend 1e2 h every week at the
MDT meeting. Most of the respondents said that the assigned time
for the meeting is not enough to discuss all the patients unless ‘you
rush through the’. Patients not reviewed at that meeting would be
deferred to next week’s meeting e causing delay to patient care:
“Too long but not long enough! People who are not discussed, they
usually get bounced onto the following week’s meeting” (Nurse 1).
The impact of deferring patients was considered to affect both
patients and the MDT meeting: “the impact of that is that things will
be delayed for a week or so, and it can roll over because when you
postpone ﬁve patients you’ll be adding it to an already overbooked
MDT list, so that would lead to another postponement, so it rolls over”
(Surgeon 2).3.4. Implementation of MDT decisions
Participants reported that the majority of the decisions made by
the MDT meeting get implemented (median response to the
question “how often does the management plan you agree during the
MDT get implemented”: 95%, range 70e100%). Themain reasons that
impede implementation of MDT decisions were patient factors e
including (i) lack of consideration of patient’s co-morbidities, (ii)
patient’s choice, and (iii) disease progression
(i) Non-consideration of patient factors by the MDT:
There was a consensus among the participants that taking into
account patient-related factors is crucial to reach a correct decision
and not doing so may lead to an inappropriate decision or the pa-
tient may refuse it and thus discordance between the MDT decision
and the administered therapy may occur: “...the patient might look
better on paper but actually physically the patient isn’t ﬁt or doesn’t
want anything done, so I think hopefully the consultant should know
that” (Nurse 2).
(ii) Patient’s choice:
Knowledge and consideration of a patient’s preferences is
another key factor that facilitates implementation of a team’s de-
cision: “If we knew what the patient’s opinion was, I think it would
save time actually and we wouldn’t necessarily have to go back and
have another discussion...” (Surgeon 1).
(iii) Disease progression:
Disease progression was mentioned as a clinical factor that can
overturn the MDT decision: “Sometimes in the intervening period,
the patient factor’s changed, they’ve become unwell, or sometimes if
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comes no longer a relevant decision” (Surgeon 5).
3.5. Strategies to improve decision-making and decision
implementation
A number of strategies were suggested by the participants to
improve the effectiveness of MDT decision-making and imple-
mentation e including better case preparation, effective team
leadership, and involvement of an anaesthetist in the MDT (to
immediately discuss whether a patient is ﬁt for surgery if this is an
option open for consideration, rather than assess this post-
meeting). More controversial views included inclusion of patients
in MDTs and not discussing all patients (as is currently mandated in
the UK). These are presented in detail in Table 3.
4. Discussion
This study explored experienced MDT members’ views of the
efﬁcacy of their team decision-making and implementation e we
speciﬁcally identiﬁed problems and also solutions to current bar-
riers in achieving decisions that are appropriate and also get
implemented as intended into patient care. The study showed that
a management plan is not always formulated for all cancer patients
that are reviewed at the MDT meeting. Furthermore, not all the
MDT decisions get adhered to in practice. Our participants esti-
mated that around 91% of the cancer patients get a decision plan at
the MDT meeting of those only 90% get implemented e these ﬁg-
ures are close to the range of non-implementation that has been
reported in the literature (4e15%)20e23 and hence corroborate and
extend previous ﬁndings using an expert-elicitation methodology
(qualitative interviews).
Key reasons for not reaching a decision plan at the time of the
MDT meeting were: lacking a ‘holistic’ approach when discussing
patients at the meeting and absence of the treating clinician or a
key member(s). Importantly, there was an overlap between the
barriers to reaching a decision at the MDT meeting and the reasonsTable 3
Strategies to improve multidisciplinary team decision-making and implementation.
Proposed strategies for improvement Representative quotes
More preparation for the case presentation
(e.g. using a proforma)
“We used to have one that the info
worked quite well”, Oncologist 2.
“We don’t have all the information
this patient till you give us all the i
just getting away with sloppy stand
Involving the patient in the MDT discussion
 For
 Against
“In my opinion the best decision-m
patient, the clinicians will decide im
“This is where I think, probably, we
will never work”, Surgeon 3.
“No, I don’t think e that’s going to
“This is a highly technical discussio
for the patient to be present at”, Su
"I think it’s just not practical. I thin
being taken but to have the patient
Effective leadership and chairing of meetings “Sometimes I feel like there should
and there is a lot of over-talk and y
“I think at the end of each patient t
clariﬁes exactly what the decision i
of things are thrown forward but n
Reﬁning the criteria for patient discussion
at MDT
“I can tell you what way we’re goin
Surgeon 3.
“... I don’t think every patient needs
watering down the MDT, protocol,
difﬁcult cases that people have lost
Involving the anaesthetist in the MDT
process
“... the surgery may be cancelled an
anaesthetist is deciding that more i
be a good idea as well”, Surgeon 7for non-implementation of MDT decisions: that was ignoring pa-
tient-related factors of co-morbidities and psychosocial factors (in
addition to disease-related factors) that may affect the imple-
mentation of such decisions. This is an important ﬁnding, as it
suggests that if these issues are addressed improvement will be
obtained both in reaching a decision on ﬁrst case presentation and
also in implementing that decision in patient care. Lack of consid-
eration of patient-related factors during MDT decision-making has
also emerged in previous studies across tumour types in both self-
report datasets18 and also in real-time MDT observations.19,24
Technological problems with the video-conferencing facilities
were reported to negatively affect the team’s decision-making.
Introduction of telemedicine goes back a few years ago, but the
perception remains that there are problems and face-to-face dis-
cussion is preferred.33,34 Interestingly, a recent Australian study
that used a similar methodology to our study to investigate MDT
communication concluded that technological solutions should
become available to MDTs so that better access to information is
ensured and that MDT members from different professional back-
grounds ﬁnd it easier to share information and communicate.32 The
international trend in centralising care means that telemedicine
will become even more pertinent in the future e with smaller
hospitals being linked into larger cancer centres to make joint de-
cisions for their patients. Improvements to this straightforward
technical element can improve the team’s ability tomake decisions,
are not controversial and should be addressed as a matter of
priority.
This study also identiﬁed strategies to improve decision-making
and implementation. Amongst these was usage of a proforma in
preparing cases for MDT discussion. To this effect, an evidence-
based checklist tool was recently developed for use in MDTs by
our group e the MDT-QuIC.35 Strong and effective chairing and
leadership of the team meeting and including an anaesthetist to
ensure patient ﬁtness for surgery were also mentioned. More
contentious strategies also emerged. The ﬁrst was the suggestion to
reﬁne the inclusion criteria for MDT discussion (so that the team
has more time to more thoroughly discuss patients), either byrmation was actually put on to that and it was projected onto a screen... it actually
(for referrals), and we don’t out of courtesy go back and say, “We are not discussing
nformation, But may be we should start doing that because otherwise they are
ards”, Surgeon 8.
aking will be done when there is a formal meeting involving the clinicians and the
mediately while the patient is there”, Surgeon 2.
need to be very careful about what we are going to make the MDT into. That
be counter-productive”, Oncologist 3.
n involving a whole bunch of experts and I don’t think that is the right format
rgeon 8.
k yes, they should be involved in a sense so that they know that a decision is
in the room, it would just be a disaster”, Oncologist 4.
be one main person leading it because it sometimes becomes a bit of a free-for-all
ou cannot hear what’s going on”, Nurse 5.
here should be a period where we say “Okay, the decision is. “and someone
s and makes sure that everyone agrees with it, because sometimes a number
o one’s actually said “Actually the decision is this.””, Surgeon 5.
g, we’re going to separate MDTs (tumour speciﬁc MDTs). I think that will help”,
to be discussed, and one of the problems we faced, the challenge, is the issue of
protocol, protocol, we end up talking about them all and you end up on the three
interest by then and sometimes you can miss...”, Oncologist 3.
d therefore the decision is not implemented/changed/delayed because the
nvestigation is required. So an anaesthetist at the time of the MDT that would
.
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from review some patients that fall under clear protocols/guide-
lines. The former suggestion may pose some logistical difﬁculties e
as it will require further meetings to be ﬁtted into already busy
clinical schedules, and hence may require amendments to job
planning for surgeons and other cancer professionals.36 The latter
suggestion is outside current mandatory practice in the UK e
however, it is perhaps an avenue to reconsider in the future. A
further contentious suggestion was inclusion of patients in the
MDT. Some thought that it would enhance the decision-making,
but others thought that this practice is counterproductive. The
latter argument replicates another recent Australian study, where
patient attendance at the MDT meeting raised concerns about pa-
tients’ ability to cope with the information discussed and the
consequences of their presence at the meeting on the decision-
making process.37 Another Australian study found that 93% of pa-
tient advocates supported the involvement of breast cancer pa-
tients in the MDT meeting while the majority of healthcare
professionals felt that it would raise patient anxiety.38 Similar
ﬁndings were obtained in a survey of MDT members in England,
where patient attendance in MDT meetings was deemed neither
practical nor desirable.39 However, a small scale pilot study in
Australia found that the attendance of breast cancer patients to the
MDT meeting was potentially acceptable to both patient and
healthcare professional without excessively raising patient anxi-
ety.40 This issue clearly deserves further study.
Certain limitations apply to our ﬁndings. Our participants were
members of urology and GI surgeryMDTs and so it is not possible to
be certain how representative the sample is of MDT members of
other specialties. Similarly, generalizability may also be hampered
by the location of the study (London, UK) e although care was
taken to sample participants from 3 hospitals. The small sample
size and indeed the self-reported nature of the data could further
limit generalisability of the ﬁndings. This is a limitation of all
qualitative studiese however, such studies are necessary if detailed
understanding of experts’ views is sought. Further validation of
these views expressed in this study should be sought via larger
scale surveys andmore objective methods of assessingMDTs in real
time, like standardised observational instruments, which are now
available.41 Importantly for our purposes here, all possible steps
were taken in the data analysis to ensure minimization of bias,
participants were recruited from a large geographical area and also
a key strength of the study is the representativeness of the pro-
fessional groups in both tumour types within the study sample. In
order to avoid recall bias within the study as much as possible, the
interviews were audio-recorded and transcribed verbatim. More-
over, previous studies in the UK and other countries have arrived at
similar conclusions using both self-report and also observational
methods, thereby lending validity to these results.
We believe that these ﬁndings can be used as a basis for
designing and implementing acceptable and thus implementable
interventions based on our respondents’ expert views. Recently
published data suggest a cost of £87.41 ($141.95) per case discussion
in a UKMDT42ewhich reinforces the point that MDT-driven care is
expensive.43 Non-implementation of an MDT decision is therefore
not only a time/prognosis problem but also a cost-related issuee as
these patients have to be re-reviewed. Our study provides an un-
derstanding of the factors that affect decision-making and imple-
mentation from the service providers’ perspective and also outlines
the strategies to tackle such barriers e some of which are more
contentious than others (including more direct patient involve-
ment in the MDT and also patient selection for MDT discussion). At
present, in the UKMDT-driven care is mandatorye and hence there
may be limits to the options immediately available to restructure
care processes or to evaluate them using the most robust design(i.e., RCT). Based on this study, we are currently analysing decision
implementation further, aiming to arrive at potential interventions
that are feasible to implement and that can enhance not only MDT
decision-making (like the MDT-QuIC checklist35) but also the like-
lihood that an MDT recommendation will be acted on. Future
research should aim to implement such strategies to streamline
cancer patient care.
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